VEGFR3-targeted therapeutics for obesity have not yet been significantly explored, although the VEGFR3 activation must be maintained or upregulated to prevent lymphatic vessel leakiness, excess adipocyte hypertrophy, and insulin resistance (Cifarelli and Eichmann, 2019). The gene discussed is FLT4; the disease is obesity due to melanocortin 4 receptor deficiency.